Clinical trial landscape analysis of stem cell therapy for autoimmune rheumatic diseases
Stem cell therapy is rapidly advancing in ARDs, supported by growing clinical evidence and technological innovations. However, standardized, multicenter phase III trials are essential to confirm long-term efficacy and safety. This evolving landscape holds potential to transform AIRD management.
Authors
- Jin Chen (ORCID: https://orcid.org/0000-0002-5557-2079)
- Huimin Wang (ORCID: https://orcid.org/0000-0003-2363-4957)
- Qiao Wang (ORCID: https://orcid.org/0000-0003-2274-5153)
- Xiaoyong Chen (ORCID: https://orcid.org/0000-0002-6817-6630)
- Jia Xu (ORCID: https://orcid.org/0000-0002-4379-5347)
Institutions
- Jiangxi Maternal and Child Health Hospital (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1097/js9.0000000000003130
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00